

Rosacea

CHI Formulary Treatment algorithm

Treatment algorithm- December
2023

Supporting treatment algorithms
for the clinical management of
Rosacea

Figure 1 outlines the **Management pathway for people with rosacea** and Figure 2 outlines the **Overview of Rosacea Treatment Options** aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Rosacea** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.




Figure 1. Management pathway for people with rosacea. Nd: YAG, neodymium-doped yttrium aluminium garnet; OTC, over the counter.

- British Association of Dermatologists guidelines for the management of people with rosacea 2021. For the level of evidence and details on the figures in the algorithm, please refer to the full report.




Figure 2. Overview of Rosacea Treatment Options

- S2k guideline: Rosacea 2022. For the level of evidence and details on the figures in the algorithm, please refer to the full report.